A nomogram for predicting the risk of venous thromboembolism in patients with solid cancers

Compared with the general population, patients with tumors are four to seven times more likely to develop venous thrombotic events.Thromboprophylaxis treatment increases the risk of bleeding complications and the risk of VTE varies widely among individuals.Only patients at high risk of thrombosis will benefit from primary thromboprophylaxis.This intuitive nomogram model with variables available in routine clinical practice to quantify the risk of VTE in patients with solid cancers and assist clinicians in tailoring anticoagulant therapy.